#patent — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #patent, aggregated by home.social.
-
#Microsoft Patents "Ad-Credit" System for PC and Consoles to Serve In-Game Ads.
Players start the game with a block of ad-free playtime (e.g., 30 minutes or 1 complete level). As the timer nears its expiration, the ad delivery system opens a brief “promoted content” window. ... From there, the ad tech freezes the game state to serve a video or static ad and rewards the viewer with a fresh “ad-credit” duration.
-
#Microsoft Patents "Ad-Credit" System for PC and Consoles to Serve In-Game Ads.
Players start the game with a block of ad-free playtime (e.g., 30 minutes or 1 complete level). As the timer nears its expiration, the ad delivery system opens a brief “promoted content” window. ... From there, the ad tech freezes the game state to serve a video or static ad and rewards the viewer with a fresh “ad-credit” duration.
-
#Microsoft Patents "Ad-Credit" System for PC and Consoles to Serve In-Game Ads.
Players start the game with a block of ad-free playtime (e.g., 30 minutes or 1 complete level). As the timer nears its expiration, the ad delivery system opens a brief “promoted content” window. ... From there, the ad tech freezes the game state to serve a video or static ad and rewards the viewer with a fresh “ad-credit” duration.
-
#Microsoft Patents "Ad-Credit" System for PC and Consoles to Serve In-Game Ads.
Players start the game with a block of ad-free playtime (e.g., 30 minutes or 1 complete level). As the timer nears its expiration, the ad delivery system opens a brief “promoted content” window. ... From there, the ad tech freezes the game state to serve a video or static ad and rewards the viewer with a fresh “ad-credit” duration.
-
#Microsoft Patents "Ad-Credit" System for PC and Consoles to Serve In-Game Ads.
Players start the game with a block of ad-free playtime (e.g., 30 minutes or 1 complete level). As the timer nears its expiration, the ad delivery system opens a brief “promoted content” window. ... From there, the ad tech freezes the game state to serve a video or static ad and rewards the viewer with a fresh “ad-credit” duration.
-
Analyse: Beim Forschungstransfer sind Sachsens Unis und Institute deutschlandweit vorn. Die #Wirtschaft fordert aber mehr verkaufbare Produkte. Wie das geht, zeigt ein @UIIN-Forum in #Dresden
https://oiger.de/2026/09/17/wirtschaft-fordert-von-sachsens-forschern-am-ende-muessen-auch-verkaufbare-produkte-herauskommen/198576
#Forschungstransfer #TUD #Innovation #DeepTech #Patent #Sachsen -
Analyse: Beim Forschungstransfer sind Sachsens Unis und Institute deutschlandweit vorn. Die #Wirtschaft fordert aber mehr verkaufbare Produkte. Wie das geht, zeigt ein @UIIN-Forum in #Dresden
https://oiger.de/2026/09/17/wirtschaft-fordert-von-sachsens-forschern-am-ende-muessen-auch-verkaufbare-produkte-herauskommen/198576
#Forschungstransfer #TUD #Innovation #DeepTech #Patent #Sachsen -
Analyse: Beim Forschungstransfer sind Sachsens Unis und Institute deutschlandweit vorn. Die #Wirtschaft fordert aber mehr verkaufbare Produkte. Wie das geht, zeigt ein @UIIN-Forum in #Dresden
https://oiger.de/2026/09/17/wirtschaft-fordert-von-sachsens-forschern-am-ende-muessen-auch-verkaufbare-produkte-herauskommen/198576
#Forschungstransfer #TUD #Innovation #DeepTech #Patent #Sachsen -
I’m still completely lost with logic of JA4+ patent licensing and actual incompatibility with the copyleft-license. So it seems to be a patent-based license and really risky to implement if you want to keep your actual software open source.
Did someone explore alternatives to avoid this? and especially other format which are open source friendly?
#ja4 #ja3 #jarm #cti #opensource #patent #cti
#threatintel #cybersecurity🔗 https://github.com/FoxIO-LLC/ja4/blob/main/License%20FAQ.md
-
I’m still completely lost with logic of JA4+ patent licensing and actual incompatibility with the copyleft-license. So it seems to be a patent-based license and really risky to implement if you want to keep your actual software open source.
Did someone explore alternatives to avoid this? and especially other format which are open source friendly?
#ja4 #ja3 #jarm #cti #opensource #patent #cti
#threatintel #cybersecurity🔗 https://github.com/FoxIO-LLC/ja4/blob/main/License%20FAQ.md
-
I’m still completely lost with logic of JA4+ patent licensing and actual incompatibility with the copyleft-license. So it seems to be a patent-based license and really risky to implement if you want to keep your actual software open source.
Did someone explore alternatives to avoid this? and especially other format which are open source friendly?
#ja4 #ja3 #jarm #cti #opensource #patent #cti
#threatintel #cybersecurity🔗 https://github.com/FoxIO-LLC/ja4/blob/main/License%20FAQ.md
-
I’m still completely lost with logic of JA4+ patent licensing and actual incompatibility with the copyleft-license. So it seems to be a patent-based license and really risky to implement if you want to keep your actual software open source.
Did someone explore alternatives to avoid this? and especially other format which are open source friendly?
#ja4 #ja3 #jarm #cti #opensource #patent #cti
#threatintel #cybersecurity🔗 https://github.com/FoxIO-LLC/ja4/blob/main/License%20FAQ.md
-
I’m still completely lost with logic of JA4+ patent licensing and actual incompatibility with the copyleft-license. So it seems to be a patent-based license and really risky to implement if you want to keep your actual software open source.
Did someone explore alternatives to avoid this? and especially other format which are open source friendly?
#ja4 #ja3 #jarm #cti #opensource #patent #cti
#threatintel #cybersecurity🔗 https://github.com/FoxIO-LLC/ja4/blob/main/License%20FAQ.md
-
'The World Health Organization (WHO) and Medicines Patent Pool (MPP) have... announced a sublicensing agreement between MPP and a Nigerian health technology company – Codix Bio – to start development and manufacturing of rapid diagnostic tests (RDTs) using technology transferred from global in-vitro diagnostics company – SD Biosensor (SDB). This agreement will contribute to advancing equitable access to vital diagnostic tools through local production, expanding manufacturing capacity in the African Region.' https://www.who.int/news/item/09-05-2025-who-and-medicines-patent-pool-announce-sublicensing-agreement-for-rapid-diagnostic-test-technology #patent #patentpools #access2meds
-
'The World Health Organization (WHO) and Medicines Patent Pool (MPP) have... announced a sublicensing agreement between MPP and a Nigerian health technology company – Codix Bio – to start development and manufacturing of rapid diagnostic tests (RDTs) using technology transferred from global in-vitro diagnostics company – SD Biosensor (SDB). This agreement will contribute to advancing equitable access to vital diagnostic tools through local production, expanding manufacturing capacity in the African Region.' https://www.who.int/news/item/09-05-2025-who-and-medicines-patent-pool-announce-sublicensing-agreement-for-rapid-diagnostic-test-technology #patent #patentpools #access2meds